Research & Literature

Krüppel-like Factor 4 Blocks Hepatocellular Carcinoma Dedifferentiation and Progression through Activation of Hepatocyte Nuclear Factor-6.

Sun H, Tang H, Xie D, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2016; (22(2)):502-12 doi:10.1158/1078-0432.CCR-15-0528.

Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient.

Wedd JP, Nordstrom E, Nydam T, et al.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2015; (21(12)):1543-52 doi:10.1002/lt.24356.

Characteristics of Hypovascular versus Hypervascular Well-Differentiated Hepatocellular Carcinoma Smaller Than 2 cm - Focus on Tumor Size, Markers and Imaging Detectability.

Sugimoto K, Kim SR, Imoto S, et al.

Digestive diseases (Basel, Switzerland) 2015; (33(6)):721-7 doi:10.1159/000439078.

Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma.

Chan AW, Kumada T, Toyoda H, et al.

Journal of gastroenterology and hepatology 2016; (31(7)):1300-6 doi:10.1111/jgh.13291.

Effect of MRI Versus MDCT on Milan Criteria Scores and Liver Transplantation Eligibility.

Rostambeigi N, Taylor AJ, Golzarian J, et al.

AJR. American journal of roentgenology 2016; (206(4)):726-33 doi:10.2214/AJR.15.14642.

Hepatocellular Carcinoma Post Embolotherapy: Imaging Appearances and Pitfalls on Computed Tomography and Magnetic Resonance Imaging.

Chiu RY, Yap WW, Patel R, et al.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes 2016; (67(2)):158-72.

Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade.

Toyoda H, Lai PB, O'Beirne J, et al.

British journal of cancer 2016; (114(7)):744-50 doi:10.1038/bjc.2016.33.

A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.

Edeline J, Blanc JF, Johnson P, et al.

Liver international : official journal of the International Association for the Study of the Liver 2016; (36(12)):1821-1828 doi:10.1111/liv.13170.

Hepatocellular carcinoma: From diagnosis to treatment.

Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, et al.

Surgical oncology 2016; (25(2)):74-85.

Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.

Pecorelli A, Lenzi B, Gramenzi A, et al.

Liver international : official journal of the International Association for the Study of the Liver 2017; (37(3)):423-433 doi:10.1111/liv.13242.

Does alpha-fetoprotein contribute to the mortality and morbidity of human hepatocellular carcinoma? A commentary.

Mizejewski GJ

Journal of hepatocellular carcinoma 2016; (3()):37-40 doi:10.2147/JHC.S114198.

Interleukin 6-dependent genomic instability heralds accelerated carcinogenesis following liver regeneration on a background of chronic hepatitis.

Lanton T, Shriki A, Nechemia-Arbely Y, et al.

Hepatology (Baltimore, Md.) 2017; (65(5)):1600-1611 doi:10.1002/hep.29004.

The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy.

Galle PR, Tovoli F, Foerster F, et al.

Journal of hepatology 2017; (67(1)):173-183 doi:10.1016/j.jhep.2017.03.007.

Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm.

Kudo M

Liver cancer 2017; (6(3)):185-188 doi:10.1159/000462199.

Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma.

Chong CC, Chan AW, Wong J, et al.

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 2018; (16(3)):163-170 doi:10.1016/j.surge.2017.07.003.

Orthotopic liver transplantation provides a survival advantage compared with resection in patients with hepatocellular carcinoma and preserved liver function.

Liu JB, Baker TB, Suss NR, et al.

Surgery 2017; (162(5)):1032-1039 doi:10.1016/j.surg.2017.07.017.

Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysis.

Liu X, Jiang H, Chen J, et al.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2017; (23(12)):1505-1518 doi:10.1002/lt.24867.

Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Burkhart RA, Pawlik TM

Cancer control : journal of the Moffitt Cancer Center 2017; (24(3)):1073274817729235 doi:10.1177/1073274817729235.

The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer.

Shiani A, Narayanan S, Pena L, Friedman M

Cancer control : journal of the Moffitt Cancer Center 2017; (24(3)):1073274817729240 doi:10.1177/1073274817729240.

Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria.

Kim Y, Stahl CC, Makramalla A, et al.

Surgery 2017; (162(6)):1250-1258 doi:10.1016/j.surg.2017.08.007.

Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity.

Shalapour S, Lin XJ, Bastian IN, et al.

Nature 2017; (551(7680)):340-345 doi:10.1038/nature24302.

Cirrhosis and LI-RADS.

Papadatos D, Fowler KJ, Kielar AZ, et al.

Abdominal radiology (New York) 2018; (43(1)):26-40 doi:10.1007/s00261-017-1425-8.

Prospective Comparison of Gd-EOB-DTPA-Enhanced MRI with Dynamic CT for Detecting Recurrence of HCC after Radiofrequency Ablation.

Imai Y, Katayama K, Hori M, et al.

Liver cancer 2017; (6(4)):349-359 doi:10.1159/000481416.

Liver resection of hepatocellular carcinoma in patients with portal hypertension and multiple tumors.

Ohkubo T, Midorikawa Y, Nakayama H, et al.

Hepatology research : the official journal of the Japan Society of Hepatology 2018; (48(6)):433-441 doi:10.1111/hepr.13047.

Liver transplant offers a survival benefit over margin negative resection in patients with small unifocal hepatocellular carcinoma and preserved liver function.

Benjamin AJ, Baker TB, Talamonti MS, et al.

Surgery 2018; (163(3)):582-586 doi:10.1016/j.surg.2017.12.005.

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Kudo M, Finn RS, Qin S, et al.

Lancet (London, England) 2018; (391(10126)):1163-1173 doi:10.1016/S0140-6736(18)30207-1.

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Journal of hepatology 2018; (69(1)):182-236 doi:10.1016/j.jhep.2018.03.019.

When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review.

Russo FP, Imondi A, Lynch EN, Farinati F

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2018; (50(7)):640-646 doi:10.1016/j.dld.2018.03.014.

Comprehensive Analysis of Factors Affecting Clinical Response and Short-Term Survival to Drug-Eluting Bead Transarterial Chemoembolization for Treatment in Patients With Liver Cancer.

Wu X, Chen R, Zheng W, Hu H

Technology in cancer research & treatment 2018; (17()):1533033818759878 doi:10.1177/1533033818759878.

Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma.

Li Z, Lei Z, Xia Y, et al.

JAMA surgery 2018; (153(10)):e182721 doi:10.1001/jamasurg.2018.2721.

A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria.

Wang YY, Zhong JH, Xu HF, et al.

Alimentary pharmacology & therapeutics 2019; (49(2)):202-210 doi:10.1111/apt.15074.

Lessons learnt from pathologic imaging correlation in the liver: an historical perspective.

Purcell Y, Copin P, Paradis V, et al.

The British journal of radiology 2019; (92(1097)):20180701 doi:10.1259/bjr.20180701.

Exosomes in hepatocellular carcinoma: a new horizon.

Chen R, Xu X, Tao Y, et al.

Cell communication and signaling : CCS 2019; (17(1)):1 doi:10.1186/s12964-018-0315-1.

Surgical resection versus ablation for early-stage hepatocellular carcinoma: A retrospective cohort analysis.

Lee GC, Ferrone CR, Vagefi PA, et al.

American journal of surgery 2019; (218(1)):157-163 doi:10.1016/j.amjsurg.2018.12.067.

Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.

Ren AH, Zhao PF, Yang DW, et al.

Journal of magnetic resonance imaging : JMRI 2019; (50(3)):746-755 doi:10.1002/jmri.26640.

Oxidative stress and hepatocarcinogenesis.

Fu Y, Chung FL

Hepatoma research 2018; (4()) doi:10.20517/2394-5079.2018.29.

Role of US LI-RADS in the LI-RADS Algorithm.

Rodgers SK, Fetzer DT, Gabriel H, et al.

Radiographics : a review publication of the Radiological Society of North America, Inc 2019; (39(3)):690-708 doi:10.1148/rg.2019180158.

Oncological Outcomes of Hepatic Resection vs Transplantation for Localized Hepatocellular Carcinoma.

Akcam AT, Saritas AG, Ulku A, Rencuzogullari A

Transplantation proceedings 2019; (51(4)):1147-1152 doi:10.1016/j.transproceed.2019.01.093.

Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia.

Jasirwan COM, Hasan I, Sulaiman AS, et al.

Current problems in cancer 2020; (44(1)):100480 doi:10.1016/j.currproblcancer.2019.05.003.

Tumor Necrosis Factor Receptor-Associated Factor 6 Promotes Hepatocarcinogenesis by Interacting With Histone Deacetylase 3 to Enhance c-Myc Gene Expression and Protein Stability.

Wu H, Yang TY, Li Y, et al.

Hepatology (Baltimore, Md.) 2020; (71(1)):148-163 doi:10.1002/hep.30801.

Circulating exosomal miR-92b: Its role for cancer immunoediting and clinical value for prediction of posttransplant hepatocellular carcinoma recurrence.

Nakano T, Chen IH, Wang CC, et al.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2019; (19(12)):3250-3262 doi:10.1111/ajt.15490.

The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies.

Li J, Wang J, Lei L, et al.

European radiology 2019; (29(12)):6519-6528 doi:10.1007/s00330-019-06294-6.

Comparison of 2 curative treatment options for very early hepatocellular carcinoma: Efficacy, recurrence pattern, and retreatment.

Kim TH, Chang JM, Um SH, et al.

Medicine 2019; (98(26)):e16279 doi:10.1097/MD.0000000000016279.

Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.

Seo N, Kim MS, Park MS, et al.

European radiology 2020; (30(1)):261-271 doi:10.1007/s00330-019-06376-5.

The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.

Tobari M, Hashimoto E, Taniai M, et al.

Journal of gastroenterology and hepatology 2020; (35(5)):862-869 doi:10.1111/jgh.14867.

Radiofrequency Ablation Following Downstaging of Hepatocellular Carcinoma by Using Transarterial Chemoembolization: Long-term Outcomes.

Shi F, Wu M, Lian SS, et al.

Radiology 2019; (293(3)):707-715 doi:10.1148/radiol.2019181991.

Utility of Inflammatory Markers in Predicting Hepatocellular Carcinoma Survival after Liver Transplantation.

Ismael MN, Forde J, Milla E, et al.

BioMed research international 2019; (2019()):7284040 doi:10.1155/2019/7284040.

Radiomic Features at Contrast-enhanced CT Predict Recurrence in Early Stage Hepatocellular Carcinoma: A Multi-Institutional Study.

Ji GW, Zhu FP, Xu Q, et al.

Radiology 2020; (294(3)):568-579 doi:10.1148/radiol.2020191470.

Liver Imaging Reporting and Data System (LI-RADS) v2018: Review of the CT/MRI Diagnostic Categories.

Kanmaniraja D, Dellacerra G, Holder J, et al.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes 2021; (72(1)):142-149 doi:10.1177/0846537119888393.

Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review.

Yang B, Liang J, Qu Z, et al.

PloS one 2020; (15(2)):e0227475 doi:10.1371/journal.pone.0227475.

Surgical resection versus radiofrequency ablation for Barcelona Clinic Liver Cancer very early stage hepatocellular carcinoma: long-term results of a single-center study.

Hsiao CY, Hu RH, Ho CM, et al.

American journal of surgery 2020; (220(4)):958-964 doi:10.1016/j.amjsurg.2020.03.017.

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Finn RS, Qin S, Ikeda M, et al.

The New England journal of medicine 2020; (382(20)):1894-1905 doi:10.1056/NEJMoa1915745.

Comparison between Child-Pugh Score and albumin-bilirubin grade in patients treated with the combination therapy of transarterial chemoembolization and sorafenib for hepatocellular carcinoma.

Wang Z, Fan Q, Wang M, et al.

Annals of translational medicine 2020; (8(8)):537 doi:10.21037/atm.2020.02.114.

Comparison of albumin-bilirubin grade versus Child-Pugh score in predicting the outcome of transarterial chemoembolization for hepatocellular carcinoma using time-dependent ROC.

Zhao S, Zhang T, Li H, et al.

Annals of translational medicine 2020; (8(8)):538 doi:10.21037/atm.2020.02.124.

Comparison between Child-Pugh score and Albumin-Bilirubin grade in the prognosis of patients with HCC after liver resection using time-dependent ROC.

Zhao S, Wang M, Yang Z, et al.

Annals of translational medicine 2020; (8(8)):539 doi:10.21037/atm.2020.02.85.

CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.

Lee S, Kim YY, Shin J, et al.

Journal of the American College of Radiology : JACR 2020; (17(10)):1199-1206 doi:10.1016/j.jacr.2020.06.005.

A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements.

Kudo M, Han KH, Ye SL, et al.

Liver cancer 2020; (9(3)):245-260 doi:10.1159/000507370.

Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.

Zhao Y, Zhang YN, Wang KT, Chen L

Biochimica et biophysica acta. Reviews on cancer 2020; (1874(1)):188391 doi:10.1016/j.bbcan.2020.188391.

New frontiers in liver resection for hepatocellular carcinoma.

Allaire M, Goumard C, Lim C, et al.

JHEP reports : innovation in hepatology 2020; (2(4)):100134 doi:10.1016/j.jhepr.2020.100134.

Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia.

Liu YW, Yong CC, Lin CC, et al.

Journal of surgical oncology 2020; (122(8)):1587-1594 doi:10.1002/jso.26183.

MWA Versus RFA in HCC: Superior? Equivalent? Will We Ever Know?

Guiu B

Cardiovascular and interventional radiology 2020; (43(11)):1619-1620 doi:10.1007/s00270-020-02635-x.

Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response.

Osho A, Rich NE, Singal AG

Hepatoma research 2020; (6()) doi:10.20517/2394-5079.2020.42.

Alpha-fetoprotein accelerates the progression of hepatocellular carcinoma by promoting Bcl-2 gene expression through an RA-RAR signalling pathway.

Zhang C, Zhang J, Wang J, et al.

Journal of cellular and molecular medicine 2020; (24(23)):13804-13812 doi:10.1111/jcmm.15962.

Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease.

Suresh D, Srinivas AN, Kumar DP

Frontiers in oncology 2020; (10()):601710 doi:10.3389/fonc.2020.601710.

Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.

Niu XK, He XF

World journal of gastroenterology 2021; (27(2)):189-207 doi:10.3748/wjg.v27.i2.189.

Serum soluble Toll-like receptor 4 and the risk of hepatocellular carcinoma in hepatitis C virus patients.

Elkammah M, Gowily A, Okda T, Houssen M

Contemporary oncology (Poznan, Poland) 2020; (24(4)):216-220 doi:10.5114/wo.2020.102818.

The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced ultrasound in detecting hepatocellular carcinoma: A meta-analysis.

Wang J, Ye X, Li J, He S

Medicine 2021; (100(6)):e24602 doi:10.1097/MD.0000000000024602.

The Nobel Prize in Physiology or Medicine-2020.

Hagymási K

Structural chemistry 2021; (32(2)):909-913 doi:10.1007/s11224-021-01731-z.

OATP1B3 Expression in Hepatocellular Carcinoma Correlates with Intralesional Gd-EOB-DTPA Uptake and Signal Intensity on Gd-EOB-DTPA-Enhanced MRI.

Zhou X, Long L, Mo Z, Li Y

Cancer management and research 2021; (13()):1169-1177 doi:10.2147/CMAR.S292197.

Adherence to the modified Barcelona Clinic Liver Cancer guidelines: Results from a high-volume liver surgery center in East Asias.

Yen YH, Cheng YF, Wang JH, et al.

PloS one 2021; (16(3)):e0249194 doi:10.1371/journal.pone.0249194.

The patient perspective in the era of personalized medicine: What about scanxiety?

Custers JAE, Davis L, Messiou C, et al.

Cancer medicine 2021; (10(9)):2943-2945 doi:10.1002/cam4.3889.

Characteristics and Early Recurrence of Hepatocellular Carcinomas Categorized as LR-M: Comparison with Those Categorized as LR-4 or 5.

Shin J, Lee S, Kim SS, et al.

Journal of magnetic resonance imaging : JMRI 2021; (54(5)):1446-1454 doi:10.1002/jmri.27650.

Living Donor Liver Transplantation: The Optimal Curative Treatment for Hepatocellular Carcinoma Even Beyond Milan Criteria.

Alim A, Erdogan Y, Dayangac M, et al.

Cancer control : journal of the Moffitt Cancer Center 2021; (28()):10732748211011960 doi:10.1177/10732748211011960.

Diagnostic Performance of Liver Imaging Reporting and Data System Version 2017 Versus Version 2018 for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Comparative Studies.

Kim YY, Lee S, Shin J, et al.

Journal of magnetic resonance imaging : JMRI 2021; (54(6)):1912-1919 doi:10.1002/jmri.27664.

Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression.

Orci LA, Sanduzzi-Zamparelli M, Caballol B, et al.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2022; (20(2)):283-292.e10 doi:10.1016/j.cgh.2021.05.002.

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Benson AB, D'Angelica MI, Abbott DE, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(5)):541-565.

Conversion therapy and maintenance therapy for primary hepatocellular carcinoma.

Zhou H, Song T

Bioscience trends 2021; (15(3)):155-160 doi:10.5582/bst.2021.01091.

Imaging After Locoregional Therapy for Hepatocellular Carcinoma With Emphasis on LIRADS Treatment Response Assessment Criteria.

Bajaj G, Sundaram K, Jambhekar K, Ram R

Seminars in ultrasound, CT, and MR 2021; (42(4)):390-404 doi:10.1053/j.sult.2021.03.002.

Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations.

Zhu XD, Huang C, Shen YH, et al.

Liver cancer 2021; (10(4)):320-329 doi:10.1159/000514313.

Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists.

Zhong BY, Wang WS, Zhang S, et al.

Journal of clinical and translational hepatology 2021; (9(4)):521-527 doi:10.14218/JCTH.2021.00049.

Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma.

Borgia M, Dal Bo M, Toffoli G

Cancers 2021; (13(17)) doi:10.3390/cancers13174387.

Prognostic Factors of Liver Transplantation for HCC: Comparative Literature Review.

Alim A, Karataş C

Journal of gastrointestinal cancer 2021; (52(4)):1223-1231 doi:10.1007/s12029-021-00730-x.

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

Cheng AL, Qin S, Ikeda M, et al.

Journal of hepatology 2022; (76(4)):862-873 doi:10.1016/j.jhep.2021.11.030.

Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity.

Tilg H, Adolph TE, Dudek M, Knolle P

Nature metabolism 2021; (3(12)):1596-1607 doi:10.1038/s42255-021-00501-9.

A Pleiotropic Role of the Hepatitis B Virus Core Protein in Hepatocarcinogenesis.

Lefeuvre C, Le Guillou-Guillemette H, Ducancelle A

International journal of molecular sciences 2021; (22(24)) doi:10.3390/ijms222413651.

Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.

Brown ZJ, Gregory S, Hewitt DB, et al.

Surgical oncology 2022; (42()):101748 doi:10.1016/j.suronc.2022.101748.

Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.

Pan J, Li W, Gu L, et al.

European radiology 2022; (32(11)):7883-7895 doi:10.1007/s00330-022-08826-z.

Diagnostic Performance of LI-RADS Version 2018 for Primary Liver Cancer in Patients With Liver Cirrhosis on Enhanced MRI.

Liu X, Ni X, Li Y, et al.

Frontiers in oncology 2022; (12()):934045 doi:10.3389/fonc.2022.934045.

Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition.

Zhang S, Zhong BY, Zhang L, et al.

World journal of gastrointestinal surgery 2022; (14(6)):528-537 doi:10.4240/wjgs.v14.i6.528.

Subsequent Treatment after Transarterial Chemoembolization Failure/Refractoriness: A Review Based on Published Evidence.

Zhang S, Wang WS, Zhong BY, Ni CF

Journal of clinical and translational hepatology 2022; (10(4)):740-747 doi:10.14218/JCTH.2021.00336.

Liver Imaging Reporting and Data System criteria for the diagnosis of hepatocellular carcinoma in clinical practice: A pictorial minireview.

Liava C, Sinakos E, Papadopoulou E, et al.

World journal of gastroenterology 2022; (28(32)):4540-4556 doi:10.3748/wjg.v28.i32.4540.

Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review.

Manjunatha N, Ganduri V, Rajasekaran K, et al.

Cureus 2022; (14(8)):e28439 doi:10.7759/cureus.28439.

Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS.

Choi SJ, Choi SH, Kim DW, et al.

Journal of hepatology 2023; (78(3)):596-603 doi:10.1016/j.jhep.2022.11.006.

Microvascular invasion risk scores affect the estimation of early recurrence after resection in patients with hepatocellular carcinoma: a retrospective study.

Wang S, Zheng W, Zhang Z, et al.

BMC medical imaging 2022; (22(1)):204 doi:10.1186/s12880-022-00940-0.

Oesophageal Varices And Associated Factors In Cirrhotic Patients With Hepatitis C.

Ali SM, Farrukh SZUI, Haqqi SAUH, et al.

Journal of Ayub Medical College, Abbottabad : JAMC 2022; (34(4)):834-837 doi:10.55519/JAMC-04-10746.

LI-RADS LR-5 on contrast-enhanced ultrasonography has satisfactory diagnostic specificity for hepatocellular carcinoma: a systematic review and meta-analysis.

Jin H, Cai Y, Zhang M, et al.

Quantitative imaging in medicine and surgery 2023; (13(2)):957-969 doi:10.21037/qims-22-591.

Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

Derry-Vick HM, Heathcote LC, Glesby N, et al.

Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.

Cao Y, Tang H, Hu B, et al.

HPB : the official journal of the International Hepato Pancreato Biliary Association 2023; (25(7)):775-787 doi:10.1016/j.hpb.2023.03.004.

Assessing the risk of surgery in patients with cirrhosis.

Kaltenbach MG, Mahmud N

Hepatology communications 2023; (7(4)) doi:10.1097/HC9.0000000000000086.

Pre- to postoperative alpha-fetoprotein ratio-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma.

Yang C, Wang H, Liu J, et al.

Frontiers in oncology 2023; (13()):1134933 doi:10.3389/fonc.2023.1134933.

Bridging locoregional treatment prior to liver transplantation for cirrhotic patients with hepatocellular carcinoma within the Milan criteria: a systematic review and meta-analysis.

Kostakis ID, Dimitrokallis N, Iype S

Annals of gastroenterology 2023; (36(4)):449-458 doi:10.20524/aog.2023.0812.

Prevalence and Risk Factors of Post-chemoembolization Syndrome After Chemo-Embolization for Hepatocellular Carcinoma in Thailand.

Thanakunchai T, Hongthanakorn C

Digestive diseases and sciences 2023; (68(9)):3818-3823 doi:10.1007/s10620-023-08010-3.

Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma.

Song X, Kelley RK, Green M, et al.

Clinical pharmacology and therapeutics 2023; (114(4)):874-882 doi:10.1002/cpt.2992.

Palliative radiotherapy for hepatic tumors: a narrative review of indications and recommendations.

Pennock M, Klein J, Lock M

Annals of palliative medicine 2023; (12(6)):1420-1446 doi:10.21037/apm-22-965.

Scan-Associated Distress in People Affected by Cancer: A Qualitative Systematic Review.

Hussain M, Chau S, Turner M, Paterson C

Seminars in oncology nursing 2023; (39(5)):151502 doi:10.1016/j.soncn.2023.151502.

Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with serum markers in at-risk patients with hepatitis B virus.

Han D, Li Y, He X, et al.

Quantitative imaging in medicine and surgery 2023; (13(10)):7156-7169 doi:10.21037/qims-23-396.

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.

Qin S, Chen M, Cheng AL, et al.

Lancet (London, England) 2023; (402(10415)):1835-1847 doi:10.1016/S0140-6736(23)01796-8.

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.

Takahashi Y, Dungubat E, Kusano H, Fukusato T

Biomedicines 2023; (11(10)) doi:10.3390/biomedicines11102761.

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.

Yano S, Kawaoka T, Yamasaki S, et al.

Cancers 2023; (15(22)) doi:10.3390/cancers15225406.

LIME-based ensemble machine for predicting performance status of patients with liver cancer.

Nguyen HV, Byeon H

Digital health 2023; (9()):20552076231211636 doi:10.1177/20552076231211636.

Prognosis and safety of laparoscopic hepatectomy for BCLC stage 0/A hepatocellular carcinoma with clinically significant portal hypertension: a multicenter, propensity score-matched study.

Xia F, Zhang Q, Ndhlovu E, et al.

Surgical endoscopy 2024; (38(2)):799-812 doi:10.1007/s00464-023-10589-7.

Hepatocellular Carcinoma Risk Scores from Modeling to Real Clinical Practice in Areas Highly Endemic for Hepatitis B Infection.

Hao X, Fan R, Zeng HM, Hou JL

Journal of clinical and translational hepatology 2023; (11(7)):1508-1519 doi:10.14218/JCTH.2023.00087.

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.

Wang K, Xiang YJ, Yu HM, et al.

Nature medicine 2024; (30(3)):708-715 doi:10.1038/s41591-023-02786-7.

MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges.

Phoolchund AGS, Khakoo SI

Cancers 2024; (16(2)) doi:10.3390/cancers16020259.

Comparison of Surgical Resection and Radiofrequency Ablation in Elderly Patients with Hepatocellular Carcinoma.

Kim JI, Lee J, Choi GH, et al.

Digestive diseases and sciences 2024; (69(3)):1055-1067 doi:10.1007/s10620-023-08245-0.

Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

Abou-Alfa GK, Lau G, Kudo M, et al.

NEJM evidence 2022; (1(8)):EVIDoa2100070 doi:10.1056/EVIDoa2100070.

Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA+ B cells.

Xie Y, Huang Y, Li ZY, et al.

Molecular cancer 2024; (23(1)):95 doi:10.1186/s12943-024-02001-2.

Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.

Sangro B, Galle PR, Kelley RK, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024; (42(23)):2790-2799 doi:10.1200/JCO.23.01462.

Comparative Efficacy of Microwave versus Radiofrequency Ablation in Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of Randomized-Controlled Trials.

Rey I, Darmadi D

Romanian journal of internal medicine = Revue roumaine de medecine interne 2024; (62(4)):374-386 doi:10.2478/rjim-2024-0022.

Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon.

Galasso L, Cerrito L, Maccauro V, et al.

International journal of molecular sciences 2024; (25(13)) doi:10.3390/ijms25137191.

Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside.

Yin Y, Feng W, Chen J, et al.

Experimental hematology & oncology 2024; (13(1)):72 doi:10.1186/s40164-024-00539-x.

Gut Microbiota, Deranged Immunity, and Hepatocellular Carcinoma.

Scarpellini E, Scarlata GGM, Santori V, et al.

Biomedicines 2024; (12(8)) doi:10.3390/biomedicines12081797.

Hepatitis B Viral Protein HBx: Roles in Viral Replication and Hepatocarcinogenesis.

Li D, Hamadalnil Y, Tu T

Viruses 2024; (16(9)) doi:10.3390/v16091361.

Grading severity of MVI impacts long-term outcomes after laparoscopic liver resection for early-stage hepatocellular carcinoma: A multicenter study.

Yang S, Ni H, Zhang A, et al.

American journal of surgery 2024; (238()):115988 doi:10.1016/j.amjsurg.2024.115988.

Benefit of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score-Matched Study.

Han R, Gan L, Sun L, et al.

Journal of hepatocellular carcinoma 2024; (11()):1835-1844 doi:10.2147/JHC.S482803.

New Insights into AMPK, as a Potential Therapeutic Target in Metabolic Dysfunction-Associated Steatotic Liver Disease and Hepatic Fibrosis.

An H, Jang Y, Choi J, et al.

Biomolecules & therapeutics 2025; (33(1)):18-38 doi:10.4062/biomolther.2024.188.

Pre-procedural virtual reality education reduces anxiety in patients undergoing atrial septal closure - Results from a randomized trial.

Oudkerk Pool MD, Hooglugt JQ, Kraaijeveld AJ, et al.

International journal of cardiology. Congenital heart disease 2022; (7()):100332 doi:10.1016/j.ijcchd.2022.100332.

How to Predict Recurrence After Resection of Hepatocellular Carcinoma.

Petruch N, Bolm L, Nebbia M, et al.

Anticancer research 2025; (45(1)):189-199 doi:10.21873/anticanres.17404.

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study.

Cai H, Chen S, Tang S, et al.

Cancer immunology, immunotherapy : CII 2025; (74(3)):88 doi:10.1007/s00262-025-03942-3.

Predicting early recurrence in hepatocellular carcinoma after hepatectomy using GD-EOB-DTPA enhanced MRI-based model.

Zeng H, Ma Z, Tao Y, et al.

European journal of radiology 2025; (188()):112130 doi:10.1016/j.ejrad.2025.112130.

Imaging-based diagnosis of hepatocellular carcinoma: Liver Imaging Reporting and Data System and beyond.

Haghshomar M, Kierans AS, Kulik L, et al.

The British journal of radiology 2025; (98(1173)):1344-1355 doi:10.1093/bjr/tqaf123.

Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma.

Lau HC, Zhang X, Yu J

Nature reviews. Gastroenterology & hepatology 2025; (22(9)):619-638 doi:10.1038/s41575-025-01089-1.

Network pharmacology integrated with molecular docking and experimental validation elucidates the therapeutic potential of Forsythiae Fructus extract against hepatitis B virus-related hepatocellular carcinoma.

Chen F, Cai Y, Chen C, Zhou J

Frontiers in oncology 2025; (15()):1571537 doi:10.3389/fonc.2025.1571537.

Development and Validation of a Radiomics Nomogram Based on Magnetic Resonance Imaging and Clinicoradiological Factors to Predict HCC TACE Refractoriness.

Dong Y, Hu J, Meng X, et al.

Cancer management and research 2025; (17()):1441-1455 doi:10.2147/CMAR.S486561.

Genetic variants underlying precancerous conditions of hepatocellular carcinoma.

Guerrero JJG, Encarnacion PC, Del Rosario MAS, et al.

International journal of cancer 2026; (158(3)):488-502 doi:10.1002/ijc.70092.

Impact of the 6-mo Wait Policy on Transplantation, Resection, and Ablation Outcomes for Patients With Hepatocellular Carcinoma: A National Cancer Database Analysis.

Hasjim BJ, Paukner M, Kwong AJ, et al.

Transplantation 2026; (110(1)):e204-e216 doi:10.1097/TP.0000000000005536.

Effectiveness of a Nurse-Led Intervention on Pre-procedural Anxiety Among Patients Undergoing Endoscopy: A Quasi-experimental Trial.

Chaudhary V, Sharma S, Kumar A, et al.

Cureus 2025; (17(9)):e93166 doi:10.7759/cureus.93166.

Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer.

Karin M, Kim JY

Pharmacological reviews 2025; (77(6)):100096 doi:10.1016/j.pharmr.2025.100096.

From bioinformatics to clinical translation: BIRC5 as a pivotal diagnostic biomarker and therapeutic target for NAFLD-driven HCC.

Huang Y, He H, Xia X, et al.

Cell biology and toxicology 2025; (42(1)):32 doi:10.1007/s10565-025-10128-1.

HCC in the Era of Emerging MASH: The Role of Ultrasound in Surveillance and New Sonographic Features in Diagnosis.

Giorgio A, De Luca M, Lombardi A, et al.

Cancers 2025; (17(24)) doi:10.3390/cancers17244037.

Exploring the lived experiences of women with metastatic breast cancer and their HRQoL questionnaire preferences: a qualitative study.

Tolstrup LK, Vogsen M, Hildebrandt MG, et al.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2026; (35(2)):32.

Landscape of Somatic and Age-Related Pathogenic Structural Variations in Hepatocellular Carcinoma Revealed by Long-Read Sequencing.

Wei Z, Cao Y, Liu H, et al.

MedComm 2026; (7(1)):e70570 doi:10.1002/mco2.70570.

RNA splicing dysregulation in hepatocellular carcinoma: Molecular mechanisms, therapeutic targets, and intervention strategies-A comprehensive review.

Xiong S, Hu L, Sun YY, et al.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2026; (195()):119025 doi:10.1016/j.biopha.2026.119025.

The Emerging Challenge of Non-Cirrhotic MASLD-Related Hepatocellular Carcinoma: Etiology, Immunopathology, and Precision Oncology.

Liu Y

Liver cancer 2025; doi:10.1159/000550163.

Survival Outcome Was Better with Liver Resection than with Percutaneous Radiofrequency Ablation in Patients with Very Early-Stage Hepatocellular Carcinoma: A Single-Center Retrospective Study.

Yen YH, Liu YW, Hung CH, et al.

Journal of investigative surgery : the official journal of the Academy of Surgical Research 2026; (39(1)):2625532 doi:10.1080/08941939.2026.2625532.